Neurotoxicity of pesticides /

Neurotoxicity of Pesticides, Volume Four, in this comprehensive serial addresses contemporary advances in neurotoxicology of pesticides by providing authoritative review articles on key issues in the field. Edited by leading subject experts, topics of note in this new release include Organophosphate...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Aschner, Michael (Editor ), Costa, Lucio G. (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cambridge, MA : Academic Press, 2020.
Colección:Advances in neurotoxicology ; v. 4.
Temas:
Pesticides > Toxicology.
Pesticides.
Pesticides
Pesticides > Toxicologie.
pesticide.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Front Cover
  • Neurotoxicity of Pesticides
  • Copyright
  • Contents
  • Contributors
  • Preface
  • Chapter One: Neuropathy target esterase (NTE/PNPLA6) and organophosphorus compound-induced delayed neurotoxicity (OPIDN)
  • 1. Introduction
  • 2. NTE definition: Gene, protein, and enzyme
  • 3. NTE and OPIDN
  • 4. Overview of OP compounds
  • 4.1. OP compounds: Uses and exposures
  • 4.2. Interactions of OP inhibitors with serine esterases
  • 4.3. Inhibition of AChE and cholinergic toxicity
  • 4.4. Aging of OP-inhibited AChE
  • 4.5. Inhibition and aging of NTE and OPIDN
  • 4.6. Jake Leg epidemic
  • 5. Rationale for NTE research
  • 6. History of NTE
  • 6.1. Importance of history
  • 6.2. M.K. Johnson and the MRC toxicology unit
  • 6.3. MRC leadership and intellectual climate
  • 6.4. MRC philosophy
  • 6.5. Mipafox incident
  • 6.6. Discovery and naming of NTE
  • 6.7. Biochemical lesion and pathogenesis
  • 6.8. Passing the torch
  • 7. Applications of NTE
  • 7.1. NTE Assay and neuropathic potential
  • 7.2. Structure-activity relationships (SARs)
  • 7.3. Protection (prophylaxis) against OPIDN
  • 7.4. Potentiation or promotion of OPIDN
  • 7.5. NTE-based biomarkers and biosensors
  • 8. Cellular and molecular biology of NTE
  • 8.1. NTE: The next generation
  • 8.2. NTE protein sequences and domains
  • 8.2.1. Canonical and isoform sequences
  • 8.2.2. Four types of domains
  • 8.2.3. Transmembrane (TM) domain
  • 8.2.4. Cyclic nucleotide binding (CNB) homology domains
  • 8.2.5. Catalytic (patatin-homology) domain (PNTE)
  • 8.2.6. Protein kinase A binding (PKAB) domain
  • 8.2.7. Posttranslational modifications (PTMs)
  • 8.3. Subcellular localization of NTE
  • 8.4. Expression of NTE in human tissues
  • 8.5. NTE knockouts, silencing, and mutations
  • 8.5.1. Conventional knockouts
  • 8.5.2. Silencing
  • 8.5.3. Conditional knockouts
  • 8.5.4. NTE disease-causing mutations in humans
  • 9. Reconciling apparent conflicts between toxicological and genetic data
  • 10. Suggested future research on elucidating the role of NTE in OPIDN
  • 10.1. Phospholipid homeostasis disruption (PHD)
  • 10.2. OP-induced Wallerian degeneration (OPIWAD)
  • 11. Conclusion
  • References
  • Chapter Two: Neurotoxicity of organophosphate nerve agents
  • 1. Introduction
  • 2. A brief historical perspective
  • 3. Chemistry of OP nerve agents
  • 4. Route of exposure
  • 5. Mechanism of action and neurotoxicity
  • 5.1. Cholinergic
  • 5.2. Noncholinergic
  • 5.3. Oxidative stress
  • 6. Dendritic damage
  • 7. Nerve agents and alterations at the blood-brain barrier
  • 8. Electrophysiological alterations (central vs peripheral) by OP nerve agents
  • 9. Nerve agents and the neuromuscular junction
  • 10. Intermediate syndrome and delayed polyneuropathy
  • 11. Neuropsychiatric effects and PTSD
  • 12. Nerve agents and brain cancer
  • 13. Biomarkers of OP nerve agent exposure and effect
  • 14. Treatment

Ejemplares similares